Skip to main content
Figure 4 | Arthritis Research & Therapy

Figure 4

From: Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study

Figure 4

Mean change of Health Assessment Questionnaire Disability Index (HAQ DI) from baseline in patients (A) with sustained low disease activity (LDA) defined as Simplified Disease Activity Index (SDAI) ≤ 11 for at least 6 months and without sustained LDA and (B) with sustained remission (REM) defined as SDAI ≤ 3.3 for at least 6 months and without sustained REM. Data are shown as observed values for all evaluable patients at each time point during long-term treatment with adalimumab (ADA). *Denotes significance from baseline, P ≤0.001. LO, last observation.

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us